Literature DB >> 33395782

New onset diabetes, type 1 diabetes and COVID-19.

Sirisha Kusuma Boddu1, Geeta Aurangabadkar2, Mohammad Shafi Kuchay3.   

Abstract

BACKGROUND AND AIMS: New data has emerged regarding higher risk of coronavirus disease 2019 (COVID-19), and its severity and complications in patients with type 2 diabetes mellitus (T2DM). However, there is a dearth of evidence regarding type 1 diabetes mellitus (T1DM). This article explores the possibility of COVID 19 induced diabetes and highlights a potential bidirectional link between COVID 19 and T1DM.
METHODS: A literature search was performed with Medline (PubMed), Scopus, and Google Scholar electronic databases till October 2020, using relevant keywords (COVID-19 induced diabetes; COVID-19 and type 1 diabetes; COVID-19 induced DKA; new-onset diabetes after SARS-CoV-2 infection) to extract relevant studies describing relationship between COVID-19 and T1DM.
RESULTS: Past lessons and new data teach us that severe acute respiratory syndrome coronaviruses (SARS-CoV and SARS-CoV-2) can enter islet cells via angiotensin converting enzyme-2 (ACE-2) receptors and cause reversible β-cell damage and transient hyperglycemia. There have been postulations regarding the potential new-onset T1DM triggered by COVID-19. This article reviews the available evidence regarding the impact and interlink between COVID-19 and Τ1DM. We also explore the mechanisms behind the viral etiology of Τ1DM.
CONCLUSIONS: SARS-CoV-2 can trigger severe diabetic ketoacidosis at presentation in individuals with new-onset diabetes. However, at present, there is no hard evidence that SARS-CoV-2 induces T1DM on it's own accord. Long term follow-up of children and adults presenting with new-onset diabetes during this pandemic is required to fully understand the type of diabetes induced by COVID-19.
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACE2 receptors; Hyperglycemia; New-onset diabetes; SARS-CoV-2; Type 1 diabetes; β-cell damage

Year:  2020        PMID: 33395782     DOI: 10.1016/j.dsx.2020.11.012

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  34 in total

Review 1.  Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19.

Authors:  Chengyu Liu; Wanyao Yan; Jiajian Shi; Shun Wang; Anlin Peng; Yuchen Chen; Kun Huang
Journal:  Front Nutr       Date:  2022-06-22

2.  Autoantibody-Negative Insulinopenic Diabetes Manifested After SARS-CoV-2 Infection: Two Cases With 9 Months of Follow-Up.

Authors:  Cornelia Then; Ines Freibothe; Jochen Seissler
Journal:  Clin Diabetes       Date:  2022-01

Review 3.  Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews.

Authors:  Jamie Hartmann-Boyce; Karen Rees; James C Perring; Sven A Kerneis; Elizabeth M Morris; Clare Goyder; Afolarin A Otunla; Olivia A James; Nandana R Syam; Samuel Seidu; Kamlesh Khunti
Journal:  Diabetes Care       Date:  2021-10-28       Impact factor: 17.152

4.  SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.

Authors:  Chien-Ting Wu; Peter V Lidsky; Yinghong Xiao; Ivan T Lee; Ran Cheng; Tsuguhisa Nakayama; Sizun Jiang; Janos Demeter; Romina J Bevacqua; Charles A Chang; Robert L Whitener; Anna K Stalder; Bokai Zhu; Han Chen; Yury Goltsev; Alexandar Tzankov; Jayakar V Nayak; Garry P Nolan; Matthias S Matter; Raul Andino; Peter K Jackson
Journal:  Cell Metab       Date:  2021-05-18       Impact factor: 27.287

Review 5.  Visceral Adipose Tissue: A New Target Organ in Virus-Induced Type 1 Diabetes.

Authors:  Danny Zipris
Journal:  Front Immunol       Date:  2021-08-04       Impact factor: 7.561

6.  Type 1 diabetes onset in Lombardy region, Italy, during the COVID-19 pandemic: The double-wave occurrence.

Authors:  Chiara Mameli; Andrea Scaramuzza; Maddalena Macedoni; Giuseppe Marano; Giulio Frontino; Ester Luconi; Ciretta Pelliccia; Barbara Felappi; Lucia Paola Guerraggio; Daniele Spiri; Patrizia Macellaro; Francesca Chiara Redaelli; Roberta Cardani; Maria Zampolli; Valeria Calcaterra; Silvia Sordelli; Elena Calzi; Anna Cogliardi; Ilaria Brambilla; Carmelo Pistone; Andrea Rigamonti; Patrizia Boracchi; Elia Biganzoli; Gian Vincenzo Zuccotti; Riccardo Bonfanti
Journal:  EClinicalMedicine       Date:  2021-08-12

7.  Does COVID-19 predispose patients to type 1 diabetes mellitus?

Authors:  Aysun Ata; Arzu Jalilova; Tarık Kırkgöz; Hafize Işıklar; Günay Demir; Yasemin Atik Altınok; Behzat Özkan; Ayşin Zeytinlioğlu; Şükran Darcan; Samim Özen; Damla Gökşen
Journal:  Clin Pediatr Endocrinol       Date:  2021-11-01

8.  Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion.

Authors:  B Pla Peris; A Á Merchante Alfaro; F J Maravall Royo; P Abellán Galiana; S Pérez Naranjo; M González Boillos
Journal:  J Endocrinol Invest       Date:  2022-01-11       Impact factor: 5.467

Review 9.  Type 1 Diabetes Mellitus in the SARS-CoV-2 Pandemic: Oxidative Stress as a Major Pathophysiological Mechanism Linked to Adverse Clinical Outcomes.

Authors:  Aikaterini Kountouri; Emmanouil Korakas; Ignatios Ikonomidis; Athanasios Raptis; Nikolaos Tentolouris; George Dimitriadis; Vaia Lambadiari
Journal:  Antioxidants (Basel)       Date:  2021-05-09

10.  Association between Hyperglycemia at Hospital Presentation and Hospital Outcomes in COVID-19 Patients with and without Type 2 Diabetes: A Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients.

Authors:  Nipith Charoenngam; Sara M Alexanian; Caroline M Apovian; Michael F Holick
Journal:  Nutrients       Date:  2021-06-26       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.